Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Microsoft, Newron, Pyrum, Qiagen, Börse München - das 4investors.de-Weekend (4investors) +++ NEWRON Aktie +3,00%

OSE IMMUNOTHERAPEUTICS Aktie

 >OSE IMMUNO Aktienkurs 
2.28 EUR    -1.6%    (TradegateBSX)
Ask: 2.3 EUR / 240 Stück
Bid: 2.242 EUR / 250 Stück
Tagesumsatz: 349 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
OSE IMMUNO Aktie über LYNX handeln
>OSE IMMUNO Performance
1 Woche: -12,0%
1 Monat: -26,8%
3 Monate: -23,6%
6 Monate: -25,6%
1 Jahr: -59,3%
laufendes Jahr: -55,8%
>OSE IMMUNOTHERAPEUTICS Aktie
Name:  OSE IMMUNOTHERAPE.EO -,20
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0012127173 / A14QXP
Symbol/ Ticker:  6OP (Frankfurt)
Kürzel:  FRA:6OP, ETR:6OP, 6OP:GR
Index:  -
Profil:  OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes and Paris, France, specializing in the development of first-in-class immunotherapies for immuno-oncology and immuno-inflammation. The company focuses on innovative as..
>Volltext..
Marktkapitalisierung:  52.68 Mio. EUR
Unternehmenswert:  65.39 Mio. EUR
Umsatz:  2.7 Mio. EUR
EBITDA:  -46.18 Mio. EUR
Nettogewinn:  -38.86 Mio. EUR
Gewinn je Aktie:  -1.74 EUR
Schulden:  36.47 Mio. EUR
Liquide Mittel:  18.1 Mio. EUR
Operativer Cashflow:  -35.09 Mio. EUR
Bargeldquote:  0.91
Umsatzwachstum:  -96.25%
Gewinnwachstum:  -200.65%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  OSE IMMUNOTHERAPEUTICS, OSE IMMUNO
Letzte Datenerhebung:  28.09.26
>OSE IMMUNO Kennzahlen
Aktien/ Unternehmen:
Aktien: 23.52 Mio. St.
Frei handelbar: 73.81%
Leerverk. Aktien: -
Rückkaufquote: -0.14%
Mitarbeiter: 64
Umsatz/Mitarb.: 0.04 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 214.37%
Bewertung:
KGV: -
KGV lG: -
KUV: 23.29
KBV: 2.19
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -1439.06%
Operative Marge: -1835.01%
Managementeffizenz:
Gesamtkaprendite: -37.3%
Eigenkaprendite: -83%
>OSE IMMUNO Peer Group
 
28.09.26 - 07:30
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update (GlobeNewswire EN)
 
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update...
23.09.26 - 07:31
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting (GlobeNewswire EN)
 
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting...
24.06.26 - 18:03
OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting (GlobeNewswire EN)
 
OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting...
03.06.26 - 20:24
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document (GlobeNewswire EN)
 
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document...
28.05.26 - 21:09
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing (GlobeNewswire EN)
 
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing...
22.05.26 - 07:33
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer (GlobeNewswire EN)
 
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer...
30.04.26 - 07:33
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position (GlobeNewswire EN)
 
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position...
27.04.26 - 07:33
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients (GlobeNewswire EN)
 
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant...
23.04.26 - 07:33
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting (GlobeNewswire EN)
 
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting...
15.04.26 - 07:33
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting (GlobeNewswire EN)
 
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meet...
14.04.26 - 18:03
OSE Immunotherapeutics Evolves its Leadership Team (GlobeNewswire EN)
 
OSE Immunotherapeutics Evolves its Leadership Team : Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively...
23.03.26 - 18:03
OSE Immunotherapeutics to Present at Upcoming Investor Conferences (GlobeNewswire EN)
 
OSE Immunotherapeutics to Present at Upcoming Investor Conferences...
16.03.26 - 07:33
OSE Immunotherapeutics Announces its 2026 Financial Calendar (GlobeNewswire EN)
 
OSE Immunotherapeutics Announces its 2026 Financial Calendar...
10.03.26 - 07:33
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth (GlobeNewswire EN)
 
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth...
02.03.26 - 18:03
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® (GlobeNewswire EN)
 
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®...
26.02.26 - 18:03
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer (GlobeNewswire EN)
 
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer...
29.01.26 - 07:33
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab (GlobeNewswire EN)
 
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab...
21.01.26 - 18:03
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) (GlobeNewswire EN)
 
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)...
09.12.25 - 07:33
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation (GlobeNewswire EN)
 
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation...
08.12.25 - 14:30
AbbVie-Deal belastet: Aktie von Ose Immunotherapeutics gibt nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Respekt vor den Fakten. Gefühl für das Wichtige. Kraft zur Unabhängigkeit. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!